Rubella virus

Viral Infections of Humans: Epidemiology and Control

Volumn , Issue , 2014, Pages 733-744

  Orenstein, Walter ^a   Reef, Susan E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929925607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4899-7448-8_31     Document Type: Chapter

References (107)

1. Smith JL. Rotheln (epidemic roseola-German measles-hybrid measles, etc.). Arch Dermatol. 1875;1:1-13.
2. Veale H. History of an epidemic of Rotheln, with observation on its pathology. Edin Med J. 1866;12:404-14.
3. Smith JL. Contributions to the study of Rötheln. Trans Int Med Congr Phil. 1881;4:14.
4. Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust. 1941;3:35-46.
5. Burgess MA. Gregg's rubella legacy 1941-1991. Med J Aust. 1991;155(6):355-7.
6. Pitt D, Keir EH. Results of rubella in pregnancy. Med J Aust. 1965;2:647-51.
7. Lundstrom R. Rubella during pregnancy: a follow-up study of children born after an epidemic of rubella in Sweden, 1951, with additional investigations on prophylaxis and treatment of maternal rubella. Acta Paediatr Scand. 1962;133(Suppl):1-110.
8. Greenberg M, Pellitteri O, Barton J. Frequency of defects in infants whose mothers had rubella during pregnancy. JAMA. 1957;165:675-8.
9. Manson MM, Logan WPD, Loy RM. Rubella and other virus infections during pregnancy (Report on Public Health and Mechanical Subjects, No. 101.) London: Her Royal Majesty's Stationery Office; 1960.
10. Weller TH, Neva FA. Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Biol Med. 1962;111:215-25.
11. Parkman PD, Buescher EL, Artenstein MS. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med. 1962;111: 225-30.
12. Witte JJ, Karchmer AW. Epidemiology of rubella. Am J Dis Child. 1969;118:107-12.
13. Plotkin SA, Orenstein W, Offit PA. Rubella surveillance. 1. Bethesda: National Communicable Disease Center, United States Department of Health, Education and Welfare; 1969.
14. Plotkin SA, Oski FA, Hartnett EM, et al. Some recently recognized manifestations of the rubella syndrome. J Pediatr. 1965;67: 182-91.
15. Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. Arch Ophthalmol. 1967;77:434-9.
16. Meyer HM, Parkman PD, Hobbins TE, et al. Attenuated rubella viruses: laboratory and clinical characteristics. Am J Dis Child. 1969;118:155-69.
17. Prinzie A, Huygelen C, Gold J, et al. Experimental live attenuated rubella virus vaccine: clinical evaluation of Cendehill strain. Am J Dis Child. 1969;118:172-7.
18. Plotkin SA, Farquhar J, Katz M, Buser F. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child. 1969;118:178-85.
19. Reef SE, Redd SB, Abernathy E, Kutty P, Icenogle JP. Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States. J Infect Dis. 2011;204 Suppl 2:S593-7.
20. Averhoff F, Zucker J, Vellozzi C, Redd S, et al. Adequacy of surveillance to detect endemic rubella transmission in the United States. Clin Infect Dis. 2006;43 Suppl 3:S151-7.
21. Upreti SR, Thapa K, Pradhan YV, Shakya G, et al. Developing rubella vaccination policy in Nepal-results from rubella surveillance and seroprevalence and congenital rubella syndrome studies. J Infect Dis. 2011;204 Suppl 1:S433-8.
22. Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, Olin P, et al. The seroepidemiology of rubella in Western Europe. Epidemiol Infect. 2000;125:347-57.
23. Cockburn WC. World aspects of the epidemiology of rubella. Am J Dis Child. 1969;118(1):112-22.
24. Nardone A, Miller E, ESEN2 Group. Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2). Euro Surveill. 2004;9:5-7.
25. Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef SE. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis. 2006;43 Suppl 3:S146-50.
26. World Health Organization. Manual for the laboratory diagnosis of measles and rubella virus infection. 2nd ed. Geneva: World Health Organization; 2007.
27. Featherstone DA, Rota PA, Icenogle J, Mulders MN, et al. Expansion of the global measles and rubella laboratory network 2005-09. J Infect Dis. 2011;204 Suppl 1:S491-8.
28. Parkman PD, et al. Studies of rubella. II. Neutralization of the virus. J Immunol. 1964;93:608-17.
29. Stewart GL, et al. Rubella-virus hemagglutination-inhibition test. N Engl J Med. 1967;276:554-7.
30. Best JM, Enders G. Laboratory diagnosis of rubella and congenital rubella. In: Banatvala JE, Peckham C, editors. Rubella viruses. London: Elsevier; 2007. p. 39-77.
31. O'Shea S, Best JM, Banatvala JE, Shepherd WM. Development and persistence of class-specific serum and nasopharyngeal antibodies in rubella vaccines. J Infect Dis. 1985;151:89-98.
32. Sarnesto A, et al. Proportions of Ig classes and subclasses in rubella antibodies. Scand J Immunol. 1985;21:275-82.
33. Wilson KM, et al. Humoral immune response to primary rubella virus infection. Clin Vaccine Immunol. 2006;13:380-6.
34. Thomas HIJ, et al. Persistence of specific IgM and low avidity specific IgG1 following primary rubella. J Virol Methods. 1992;39:149-55.
35. World Health Organization. Manual for the laboratory diagnosis of measles and rubella virus. 2nd ed. Geneva: World Health Organization; 2007.
36. Abernathy E, Cabezas C, Sun H. Confirmation of rubella within 4 days of rash onset: comparison of rubella virus RNA detection in oral fluid with immunoglobulin M detection in serum or oral fluid. J Clin Microbiol. 2009;47:182-8.
37. Wolinsky JS. Rubella. In: Fields BN, Knipe DM, Hawley PM, editors. Fields' virology. New York: Raven Press; 1996. p. 899-929.
38. World Health Organization. Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses. Wkly Epidemiol Rec. 2005;80:126-32.
39. World Health Organization. Update of standard nomenclature for wild-type rubella viruses, 2007. Wkly Epidemiol Rec. 2007;82: 216-22.
40. Abernathy ES, Hubschen JM, Muller CP, et al. Status of global virologic surveillance for rubella viruses. J Infect Dis. 2011;204 Suppl 1:S524-32.
41. Zheng DP, Frey TK, Icenogle J, et al. Global distribution of rubella virus genotypes. Emerg Infect Dis. 2003;9(12):1523-30.
42. Zhu Z, Abernathy E, Cui A, et al. Rubella virus genotypes in the People's Republic of China between 1979 and 2007: a shift in endemic viruses during the 2001 Rubella Epidemic. J Clin Microbiol. 2010;48:1775-81.
43. Preblud SR, Serdula MK, Frank Jr JA, Hinman AR. From the Center for Disease Control: current status of rubella in the United States, 1969-1979. J Infect Dis. 1980;142:776-9.
44. Hinman AR, Preblud SR, Brandling-Bennett AD. Rubella: the U.S. experience. Dev Biol Stand. 1978;43:315-26.
45. CDC. Prelicensing statement on rubella virus vaccine: recommendation of the Public Health Service Advisory Committee on Immunization Practices. MMWR. 1969;18.
46. Preblud SR, Serdula MK, Frank Jr JA, Brandling-Bennett AD, Hinman AR. Rubella vaccination in the United States: a ten-year review. Epidemiol Rev. 1980;2:171-94.
47. Williams NM, Preblud SR. Current epidemiology of rubella in the United States. In: Proceedings of 19th National Immunization Conference (Boston, MA). Centers for Disease Control 1984. p. 11-17.
48. Preblud SR, Hinman AR. Remaining problems with rubella. Infect Dis. 1980;10:1, 3, 6, 7, 22.
49. CDC. Rubella surveillance, January 1976-December 1978. Atlanta: CDC; 1980.
50. CDC. Rubella vaccine: recommendation of the Immunization Practices Advisory Committee (ACIP). MMWR. 1978;27:451-4, 459.
51. Bart KJ, Orenstein WA, Preblud SR, Hinman AR, Lewis Jr FL, Williams NM. Elimination of rubella and congenital rubella from the United States. Pediatr Infect Dis. 1985;4:14-21.
52. Williams NM, Preblud SR. Rubella and congenital rubella surveillance, 1983. MMWR CDC Surveill Summ. 1984;33(4):1SS-10.
53. CDC. Rubella-United States, 1979-1982. MMWR. 1982;31: 573-5.
54. Orenstein WA, Bart KJ, Hinman AR, et al. The opportunity and obligation to eliminate rubella from the United States. JAMA. 1984;251:1988-94.
55. Public Health Service. Promoting health/preventing disease: objectives for the nation. Washington, DC: Public Health Service; 1980.
56. CDC. Rubella prevention. Recommendation of the Immunization Practices Advisory Committee. MMWR. 1981;30:37-41, 47.
57. Lindegren ML, Fehrs LJ, Hadler SC, Hinman AR. Update: rubella and congenital rubella syndrome, 1980-1990. Epidemiol Rev. 1991;13:341-8.
58. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives-full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service; 1990, DHHS publication no. (PHS) 91-50212.
59. Reef SE, Frey TK, Theall K, Abernathy E, Burnett CL, Icenogle J, McCauley MM, Wharton M. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA. 2002;287:464-72.
60. Papania M, et al. Elimination of endemic measles, rubella and congenital rubella syndrome from the Western Hemisphere-The United States Experience. JAMA Pediatr. 2014;168(2):148-55.
61. Centers for Disease Control and Prevention (CDC). Three cases of congenital rubella syndrome in the post-elimination era-Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(12):226-9.
62. Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica. 2003;14(5):306-15.
63. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS. Bull World Health Organ. 1997;75(1):55-68.
64. World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;86(29):301-16.
65. Chan CM, Tsang HF. Rubella in Hong Kong. Public health and epidemiology bulletin, Department of Health, Hong Kong. 1995;4(3):17-20.
66. Schatzmayr HG. Aspects of rubella infection in Brazil. Rev Infect Dis. 1985;7 Suppl 1:S53-5.
67. Owens CS, Espino RT. Rubella in Panama: still a problem. Pediatr Infect Dis J. 1989;8:110-5.
68. Marquez A, Zapata MT. Epidemiology of rubella in the province of Cordoba, Argentina. Bol Oficina Sanit Panam. 1984;97(1):14-25 (in Spanish).
69. Desudchit P, Chatiyanonda K, Bhamornsathit S. Rubella antibody among Thai women of childbearing age. Southeast Asian J Trop Med Public Health. 1978;9(3):312-6.
70. Intaraprasert S, Prasertsawat PO, Phiromsawat S. Postpartum rubella immunization: Ramathibodi experience in March-April 1986. J Med Assoc Thai. 1988;71 Suppl 1:94-7.
71. Phiromsawat S, et al. Rubella: a serologic study in pregnant women at Ramathibodi Hospital (1984-1985). J Med Assoc Thai. 1988;71 Suppl 2:26-8.
72. Castillo-Solórzano C, Marsigli C, Bravo-Alcántara P, et al. Elimination of rubella and congenital rubella syndrome in the Americas. J Infect Dis. 2011;204 Suppl 2:S571-8.
73. Janta D, Stanescu A, Lupulescu E, Molnar G, Pistol A. Ongoing rubella outbreak among adolescents in Salaj, Romania, September 2011-January 2012. Euro Surveill. 2012;17(7):pii=20089. http://www. eurosurveillance.org/images/dynamic/EE/V17N07/art20089.pdf .
74. Paradowska-Stankiewicz I, Czarkowski M, Derrough T, Stefanoff P. Ongoing outbreak of rubella among young male adults in Poland: increased risk of congenital rubella infections. Euro Surveill. 2013;18(21):pii=20485. http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=20485 .
75. Centers for Disease Control and Prevention (CDC). Nationwide rubella epidemic-Japan, 2013. MMWR Morb Mortal Wkly Rep. 2013;62:457-62.
76. Goodson JL, Masresha B, Dosseh A, Byabamazima C, Nshimirimana D, Cochi S, Reef S. Rubella epidemiology in Africa in the prevaccine era, 2002-2009. J Infect Dis. 2011;204 Suppl 1:S215-25.
77. Al-Nakib W, Best JM, Banatvala JE. Rubella-specific serum and nasopharyngeal immunoglobulin responses following naturally acquired and vaccine induced infection; prolonged persistence of virus-specific IgM. Lancet. 1975;1(7900):182-5.
78. Buimovici-Klein E, Cooper LZ. Cell-mediated immune response in rubella infections. Rev Infect Dis. 1985;7 Suppl 1:S123-8.
79. Buimovici-Klein E, Vesikari T, et al. Study of the lymphocyte in vitro response to rubella antigen and phytohaemagglutinin by a whole blood method. Arch Virol. 1976;52:323-31. 5:182-5.
80. Lawton AR, et al. Ontogeny of lymphocytes in the human fetus. Clin Immunol Immunopathol. 1972;1:104.
81. Bellanti JA, et al. Congenital rubella: clinicopathologic, virologic, and immunologic studies. Am J Dis Child. 1965;110:464.
82. Alford Jr CA. Studies on antibody in congenital rubella infections. I. Physicochemical and immunologic investigations of rubellaneutralizing antibody. Am J Dis Child. 1965;110:455.
83. Buescher EL. Behavior of rubella virus in adult populations. Arch Gesamte Virusforsch. 1965;16:470-6.
84. Green RH, Balsamo MR, Giles JP, Krugman S, Mirick GS. Studies of the natural history and prevention of rubella. Am J Dis Child. 1965;110(4):348-65.
85. Chaari A, Bahloul M, Berrajah L, Kahla SB, Gharbi N, Karray H, Bouaziz M. Childhood rubella encephalitis: diagnosis, management, and outcome. J Child Neurol. 2012.
86. Cooper LZ. The history and medical consequences of rubella. Rev Infect Dis. 1985;7 Suppl 1:S2-10.
87. Sever JL, Schiff GM, Huebner RJ. Inactivated rubella virus vaccine. J Lab Clin Med. 1963;62:1015.
88. Parkman PD, Meyer HM, Kirschstein BL, Hopps HE. Attenuated rubella virus. I. Development and laboratory characterization. N Engl J Med. 1966;275:569-74.
89. Perkins FT. Licensed vaccines. Rev Infect Dis. 1985;7 Suppl 1:S73-6.
90. Yaru H, Zhao K, Yinxiang G, Sulan H, Shuzhen W, Changtai W. Rubella vaccine in the People's Republic of China. Rev Infect Dis. 1985;7 Suppl 1:S79.
91. Kakizawa J, Nitta Y, Yamashita T, Ushijima H, Katow S. Mutations of rubella virus vaccine TO-336 strain occurred in the attenuation process of wild progenitor virus. Vaccine. 2001;19:2793-2-802.
92. Bottiger M, Heller L. Experiences from vaccination and revaccination of teenage girls with three different rubella vaccines. J Biol Stand. 1976;4(2):107-14.
93. Freestone DS, Prydie J, Smith SG, Laurence G. Vaccination of adults with Wistar RA 27/3 rubella vaccine. J Hyg (Lond). 1971; 69(3):471-7.
94. Fogel A, Moshkowitz A, Rannon L, Gerichter CB. Comparative trials of RA 27-3 and Cendehill rubella vaccines in adult and adolescent females. Am J Epidemiol. 1971;93(5):392-8.
95. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebocontrolled trial in twins. Lancet. 1986;1(8487):939-42.
96. Howson CP, Howe CJ, Fineberg HV. Chronic arthritis. In: Institute of Medicine, Howson CP, Howe CJ, Fineberg HV, editors. Adverse effects of pertussis and rubella vaccines. Washington, DC: National Academy Press; 1991. p. 196.
97. IOM (Institute of Medicine). Adverse effects of vaccines: evidence and causality. Washington, DC: National Academics Press; 2011. p. 89-210, 574-6.
98. Meyer Jr HM, Parkman PD. Rubella vaccination. A review of practical experience. JAMA. 1971;215(4):613-9.
99. Mogabgab WJ, Stowe Jr FR. Evaluation of attenuated rubella virus vaccine in families. Am J Dis Child. 1971;122(2):122-8.
100. World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2000;75:161-9.
101. World Health Organization (WHO). Report of a meeting on preventing congenital rubella syndrome: immunization strategies, surveillance needs, vol.10 Geneva: WHO Departments of Vaccines and Biologicals; 2000. p. 1-77.
102. Castillo-Solórzano C, Reef SE, Morice A, et al. Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001-2008. J Infect Dis. 2011;204 Suppl 2:S713-7.
103. Best JM, Reef SE. Module 11: rubella. The immunological basis for immunization series. Geneva: World Health Organization; 2008.
104. Bosma TJ, et al. Nucleotide sequence analysis of a major antigenic domain of 22 rubella virus isolates. J Gen Virol. 1996;77: 2523-30.
105. Best JM, et al. Fetal infection after maternal reinfection with rubella: criteria for defining reinfection. Br Med J. 1989;299: 773-5.
106. Balfour HH, et al. Rubella viraemia and antibody responses following rubella vaccination and reimmunization. Lancet. 1981;1: 1078-80.
107. Morgan-Capner P, Crowcroft NS, PHLS Joint Working Party of the Advisory Committees of Virology and Vaccines and Immunization. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun Dis Public Health. 2002;5 Suppl 1:59-71.